The FDA recently issued a letter warning a CBD eye drop maker about potential risks associated with its product.
Trew Vision CBD Eye Drops, which are for sale in the United States, were called "especially concerning from a public health perspective," by the agency.
"Ophthalmic drug products, which are intended for administration into the eyes, in general pose a greater risk of harm to users because the route of administration for this product bypasses some of the body’s natural defenses," the FDA wrote.
According to the FDA, the eye drops are considered a drug since it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and/or intended to affect the structure or any function of the body. The agency pointed out that Trew Vision said its product:
- Protects from macular degeneration
- Reduces the risk of diabetic retinopathy
- Protects against computer radiation exposure
- Acts as an optic nerve tonic to protect the eyes
- Great antibacterial and antiseptic properties
- Reduces stress and fatigue
- Excellent eye drops for relaxation
- Protects from glaucoma
- Helps in treating pink eye
- Helps in treating sore eyes
The FDA's letter is intended to inform the company of its concerns and provide it with an opportunity to address them. It said that if Trew Vision doesn't adequately address this matter, it may result in legal action including seizure and injunction.
Earlier this year, the FDA issued a similar warning letter to Pico IV, a startup that manufactures injectable CBD.
